Analyst firms · Citigroup · TXG
Citigroup TXG price target and rating history
10x Genomics Inc. (TXG) · Industrials
Citigroup rates 10x Genomics Inc. (TXG) Neutral with a $150 price target, as of its latest action on Dec 11, 2025. It has published 3 rating actions on TXG since August 2021, including 0 upgrades and 1 downgrade. Across 4 firms with a TXG price target in the last 12 months, the median target is $69.
- Current rating
- Neutral
- Price target
- $150
- Median target, all firms
- $69
- Actions on TXG
- 3
Citigroup price target on TXG
Every Citigroup rating on TXG
- Dec 11, 2025
- Feb 17, 2022
- Aug 5, 2021
How other firms rate TXG
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Stephens | Equal-Weight | Oct 23, 2026 | |
| Argus Research | Buy | $110 | Sep 28, 2026 |
| UBS | Neutral | $68 | Sep 9, 2026 |
| RBC Capital Markets | Sector Perform | $70 | Sep 1, 2026 |
| William Blair | Outperform | Mar 31, 2026 | |
| Citigroup | Neutral | Dec 11, 2025 | |
| Morgan Stanley | Equal-Weight | $20 | Dec 2, 2025 |
Questions about Citigroup and TXG
- What is Citigroup's price target for TXG?
- Citigroup's latest stated price target for 10x Genomics Inc. (TXG) is $150, from its action on Feb 17, 2022.
- What is Citigroup's rating on TXG?
- Citigroup rates TXG Neutral, a neutral rating, as of Dec 11, 2025.
- When did Citigroup last change its view on TXG?
- On Dec 11, 2025, Citigroup downgrades to Neutral from Buy.
- How does Citigroup's TXG target compare with other analysts?
- Across 4 firms with a TXG price target in the last 12 months, the median target is $69.
More TXG rating histories
All Citigroup ratingsTXG news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.